

Analgesic Nephropathy In 2026: Risk Factors, Pathophysiology, And Prevention Strategies

Shimaa Hamad Elneel Ahmed Elrayah*

Internal medicine senior specialist, Revive medical center, Qatif, KSA.

***Corresponding Author:** Shimaa Hamad Elneel Ahmed Elrayah., Internal medicine senior specialist, Revive medical center, Qatif, KSA.

Received Date: September 09, 2026 | **Accepted Date:** September 28, 2026 | **Published Date:** October 09, 2026

Citation: Ahmed Elrayah SHE (2026), Analgesic Nephropathy In 2026: Risk Factors, Pathophysiology, And Prevention Strategies, *International Journal of Clinical Case Reports and Reviews*, 37(3); DOI:10.31579/2690-4861/1162

Copyright: © 2026, Shimaa Hamad Elneel Ahmed Elrayah. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract:

Analgesic nephropathy (AN) remains a critical yet under-recognized cause of chronic tubulointerstitial nephritis and progressive renal injury in contemporary internal medicine. While historically associated with phenacetin abuse, the clinical landscape in 2026 is driven by chronic, high-dose combination regimens of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (paracetamol), often augmented by caffeine or codeine. This narrative review addresses three primary objectives: summarizing current epidemiological trends and risk factors, highlighting the synergistic nephrotoxicity of combination analgesics and host hemodynamic vulnerabilities; detailing the dual-pathway pathophysiological mechanisms that cause medullary vasoganglion ischemic injury and toxic metabolite-induced oxidative stress, progressing to renal papillary necrosis (RPN) and chronic tubulointerstitial nephritis (CIN); and presenting a practical, ward-based action plan for internists encompassing targeted admission medication reconciliation, protection of renal autoregulation, safe inpatient multimodal pain protocols, and patient education. Early identification and systematic de-prescribing remain the cornerstone of preventing irreversible end-stage kidney disease.

Key words: Analgesic nephropathy; chronic tubulointerstitial nephritis; renal papillary necrosis

1.Introduction

Analgesic nephropathy (AN) is a distinct form of chronic tubulointerstitial nephritis (CIN) pathologically defined by renal papillary necrosis (RPN) and secondary cortical atrophy, resulting from long-term, cumulative consumption of combination analgesic agents [1,2]. Originally recognized in the mid-20th century in connection with phenacetin overuse, the systematic withdrawal of phenacetin from global markets led to a dramatic drop in classic high-incidence clusters of AN [3,4]. However, in 2026, the clinical perception that analgesic-induced kidney injury is a disease of the past is dangerously flawed [5]. Modern analgesic practices—characterized by widespread over-the-counter (OTC) accessibility, widespread self-medication for chronic pain, and fixed-dose multi-ingredient formulations—have sustained a major burden of drug-induced kidney disease [6,7]. Contemporary analgesic nephropathy presents major diagnostic challenges to general internists and hospitalists [8]. The clinical course is characteristically indolent and non-specific, with loss of renal function occurring silently over years [9,10]. Patients frequently present during hospital admissions for unrelated acute illnesses, at which point subtle acute-on-chronic kidney injury (AKI) is detected [11,12]. Because over-the-counter pain relievers

are widely regarded by the public as harmless, patients rarely report their cumulative analgesic consumption unless specifically cross-examined during medication reconciliation [13,14]. This narrative review provides a comprehensive, up-to-date analysis of analgesic nephropathy in 2026, focusing on epidemiological shifts, modern risk factors, dual-pathway pathophysiological mechanisms, diagnostic imaging criteria, and actionable ward-based strategies for inpatient management and prevention.

2. Epidemiology And Modern Risk Factors

The epidemiological profile of analgesic nephropathy has evolved significantly over the past three decades [15]. While historical AN was dominated by middle-aged women abusing phenacetin-containing powders, modern AN affects a broader demographic, including elderly individuals and patients suffering from chronic musculoskeletal disorders, osteoarthritis, low back pain, and refractory migraines [16,17]. Recent observational studies and renal registry data indicate that chronic NSAID and acetaminophen abuse accounts for 3% to 8% of all end-stage kidney disease (ESKD) cases globally, with higher proportions in health systems where multi-agent analgesics are sold without prescription [18,19].

2.1 Synergistic Toxicity of NSAID and Acetaminophen Combinations

The fundamental epidemiological hazard in modern AN stems from the synergistic nephrotoxicity of combination analgesic abuse [20]. Formulations combining an NSAID (e.g., ibuprofen, naproxen, diclofenac) with acetaminophen (paracetamol), often augmented by central adjuvants such as caffeine, codeine, or diphenhydramine, remain widely popular [21,22]. Clinical and epidemiological evidence confirms that habitual intake of combination analgesics confers a 2.5- to 3.8-fold higher risk of developing progressive CKD compared to single-agent therapy at equivalent doses [23,24]. Caffeine acts as an adenosine receptor antagonist and mild CNS stimulant, which not only enhances perceived pain relief but also fosters psychological dependency, driving habitual daily consumption [25,26]. A cumulative lifetime intake of ≥ 1.0 to 2.0 kilograms of active analgesic compounds, or continuous daily use for more than 3 to 5 years, represents the classic exposure threshold for structural medullary damage [27,28].

2.2 Vulnerable Host Populations and Hemodynamic Modifiers

The development and severity of analgesic nephropathy are modulated by host hemodynamic vulnerabilities [29]. In hospitalized patients, underlying medical comorbidities frequently amplify renal susceptibility to analgesic injury [30]. Advanced age (>65 years) is a major independent risk factor due to age-related nephron loss, reduced renal blood flow, and blunted autoregulatory capacity [31,32]. Patients with pre-existing CKD, diabetic nephropathy, congestive heart failure, hepatic cirrhosis, or volume depletion rely heavily on renal prostaglandin synthesis to maintain glomerular perfusion [33,34]. In the acute ward setting, the 'triple whammy' interaction represents a high-risk clinical scenario [35,36]. The simultaneous administration of an NSAID, a renin-angiotensin-aldosterone system (RAAS) blocker (ACE inhibitor or ARB), and a loop or thiazide diuretic severely compromises renal autoregulation [37,38]. Diuretics reduce extracellular volume; RAAS blockers abolish efferent arteriolar vasoconstriction; and NSAIDs inhibit prostaglandin-mediated afferent arteriolar vasodilation [39]. This convergence causes rapid drops in intraglomerular capillary pressure, precipitating ischemic acute tubular necrosis or acute-on-chronic kidney injury [40,41].

3. Pathophysiological Mechanisms

The pathogenesis of analgesic nephropathy operates via a dual-pathway injury cascade combining microvascular hemodynamic ischemia and direct metabolite-mediated cellular cytotoxicity [42,43]. This localized toxic concentration selectively destroys the renal medulla and papillae, generating the hallmark lesions of renal papillary necrosis (RPN) and secondary chronic tubulointerstitial nephritis (CIN) [44,45].

3.1 Prostaglandin Blockade and Renal Medullary Ischemia

Renal vasodilatory prostaglandins—principally PGE₂ and PGI₂—are produced in renal cortical and medullary tissues via cyclooxygenase enzymes COX-1 and COX-2 [46,47]. PGE₂ and PGI₂ maintain afferent arteriolar dilatation and sustain microvascular blood flow through the medullary vasa recta [48]. The inner renal medulla naturally exists in a state of borderline hypoxia, with tissue oxygen tension (pO₂) ranging between 10 and 20 mmHg despite high total renal blood flow [49,50]. Inhibition of COX-1 and COX-2 by NSAIDs abolishes protective prostaglandin synthesis, producing intense vasoganglion constriction in the vasa recta [51,52]. Medullary hypoperfusion impairs oxygen delivery

to high-metabolic energy-demanding tubular segments, specifically the thick ascending limb of Henle's loop and medullary collecting ducts [53]. Ischemic endothelial damage induces microvascular thrombosis, capillary loss, and severe ischemic tissue necrosis at the papillary tip [54].

3.2 Acetaminophen Bioactivation and Direct Oxidative Cytotoxicity

While NSAIDs induce vasoganglion ischemia, acetaminophen exerts direct biochemical toxicity within medullary cells [55,56]. In the renal medulla, acetaminophen undergoes bioactivation by cytochrome P450 enzymes (CYP2E1) and prostaglandin H synthase into N-acetyl-p-benzoquinone imine (NAPQI), an electrophilic reactive intermediate [57,58]. Under high cumulative exposures, NAPQI exhausts medullary glutathione (GSH) antioxidant stores [59]. Depletion of glutathione enables NAPQI to bind covalently to intracellular renal proteins, damaging mitochondrial respiratory chains, inducing lipid peroxidation, and generating abundant reactive oxygen species (ROS) [60,61]. This cellular oxidative stress is concentrated by the renal countercurrent multiplication system, which concentrates acetaminophen and its metabolites up to 20-fold higher in the inner medulla than in systemic circulation [62,63].

3.3 Progression from Papillary Necrosis to Chronic Interstitial Nephritis

The interaction between NSAID-induced medullary ischemia and acetaminophen-induced oxidative toxicity leads to necrosis of the renal papillae [64,65]. Papillary tips undergo patchy, focal necrosis that coalesces into confluent renal papillary necrosis (RPN) [66]. Necrotic papillae may detach into the pelvicalyceal system, potentially causing ureteral colic or obstructive uropathy [67].

Following papillary destruction, retrograde degeneration of overlying nephrons occurs [68,69]. Obstruction of collecting tubules causes upstream cortical tubular atrophy, loss of peritubular capillaries, and an extensive inflammatory infiltrate composed of T lymphocytes, macrophages, and plasma cells [70,71]. Pro-fibrotic cytokines, including transforming growth factor-beta 1 (TGF- β 1), drive interstitial fibroblast activation and collagen deposition [72]. Over months to years, this process transforms focal papillary lesions into diffuse chronic tubulointerstitial nephritis (CIN) with secondary glomerulosclerosis, driving progressive loss of GFR [73,74].

4. Clinical Presentation, Diagnostics, And Imaging

Analgesic nephropathy is clinically insidious, often remaining asymptomatic until advanced CKD (Stage 4 or 5) develops [75]. Early functional deficits reflect medullary damage, including impaired urinary concentrating ability (isosthenuria, nocturia), Type 4 renal tubular acidosis, and urinary sodium wasting [76,77]. Urinalysis typically reveals a 'bland' sediment, mild non-nephrotic proteinuria (<1.0 g/day), and sterile pyuria (leukocyturia without urinary tract infection) [78,79].

4.1 Diagnostic Imaging Criteria on Non-Contrast CT

Non-contrast computed tomography (NCCT) is the imaging modality of choice for confirming analgesic nephropathy [80,81]. The pathognomonic NCCT triad consists of: (1) bilaterally decreased renal volume; (2) bumpy or wavy renal contours caused by cortical scar depressions overlying necrotic papillae; and (3) calcified renal papillae [82,83]. In individuals with a verified history of long-term analgesic abuse, this NCCT triad demonstrates a sensitivity of 87% and specificity exceeding 95% [84].

4.2 Biomarkers and Urothelial Malignancy Risk

Novel tubular injury biomarkers, including Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and N-acetyl- β -D-glucosaminidase (NAG), allow detection of active tubulointerstitial stress prior to overt serum creatinine elevations [85,86]. A well-established late complication of chronic AN is an increased risk of urothelial carcinoma (transitional cell carcinoma) of the renal pelvis, ureter, or bladder, mediated by chronic carcinogenic metabolite exposure [87,88]. Internists must promptly evaluate unexplained hematuria or flank pain in AN patients with urine cytology and urological imaging [89].

5. Practical Approach for Internists in the Ward Setting

Hospital admission presents both a risk and an opportunity for patients with analgesic nephropathy [90]. Acute intercurrent illness, dehydration, diagnostic contrast media, and inpatient drug prescriptions can aggravate baseline kidney injury [91]. A structured, ward-based approach enables internists to identify AN early, prevent iatrogenic AKI, and initiate safe inpatient pain control.

5.1 Targeted Inpatient Admission Medication Reconciliation

Routine admission medication records often fail to capture over-the-counter pain medications [92]. Internists should implement a structured analgesic history for all patients admitted with unexplained CKD, sterile pyuria, or high-risk profiles [93]. Clinicians should specifically ask about brand-name OTC remedies, multi-ingredient cold/flu medications, topical formulations, and daily tablet consumption counts to calculate estimated lifetime cumulative analgesic exposure [94].

5.2 Autoregulation Protection and De-prescribing Protocols

When AN or active analgesic abuse is identified, all NSAIDs (including COX-2 inhibitors) and nephrotoxic combination products must be immediately discontinued [95]. During acute ward stays involving volume depletion, sepsis, or acute intercurrent illness, internists should temporarily hold RAAS inhibitors and diuretics to preserve renal autoregulation and avoid 'triple whammy' hemodynamic failure [96,97].

5.3 Inpatient Multimodal Pain Management

Stopping habituated analgesics without substituting effective alternative pain control leads to poor patient satisfaction and non-compliance [98]. Internists should utilize a nephro-protective multimodal analgesia strategy [99]. Acetaminophen at reduced total daily doses (≤ 2.0 g/day in divided doses) can be safely utilized for mild pain in patients without hepatic impairment [100]. Neuropathic or somatic pain may be managed with dose-adjusted gabapentinoids, topical lidocaine 5% patches, or short-term low-dose atypical opioids (e.g., buprenorphine or tramadol adjusted for eGFR) alongside early physical therapy consultation [101,102].

6. Prevention Strategies and Patient Education

Preventing analgesic nephropathy requires coordinated action spanning clinical de-prescribing, patient health literacy education, and health system quality controls [103]. Complete cessation of offending analgesics is the paramount factor governing kidney outcomes; clinical studies confirm that early drug discontinuation leads to stabilization or improvement in eGFR in up to 60% of patients with mild-to-moderate CIN [104,105].

6.1 Patient Education and Discharge Counseling

Discharge counseling must explicitly challenge the pervasive belief that over-the-counter pain relievers are harmless [106]. Internists should inform patients that OTC status does not guarantee renal safety, particularly when taken daily or in combination [107]. Patients should be taught to read product packaging labels to avoid accidental double-dosing of acetaminophen or NSAIDs contained in multi-ingredient cold and flu remedies [108]. Providing a written 'Nephro-Protective Discharge Care Plan' ensures primary care physicians and outpatient pharmacists reinforce these safety parameters [109].

6.2 Health System and Regulatory Safeguards

At the health system level, electronic health record (EHR) clinical decision support systems (CDSS) serve as vital safeguards [110]. Automated EHR alerts that flag NSAID orders in patients with baseline eGFR < 60 mL/min/1.73m² or trigger warnings during concurrent 'triple whammy' prescriptions significantly lower inappropriate inpatient drug exposure [111,112]. Furthermore, public health policies restricting over-the-counter pack sizes of combination analgesics and mandating prominent kidney warning labels on packaging remain highly effective population-level strategies [113,114].

7. Conclusion

Analgesic nephropathy in 2026 represents a major, preventable cause of chronic kidney disease and acute-on-chronic renal breakdown. The shift from phenacetin to widespread self-administration of NSAID and acetaminophen combinations has obscured its recognition without reducing its nephrotoxic potential. Understanding the dual pathophysiological pathways—prostaglandin-mediated medullary vasodilation ischemia and metabolite-driven oxidative cytotoxicity—allows general internists to interpret early diagnostic markers on non-contrast CT and novel tubular biomarkers. By executing structured admission medication reconciliation, preventing 'triple whammy' hemodynamic collapse, establishing safe inpatient multimodal pain pathways, and delivering clear patient discharge counseling, internists can preserve functional nephrons and halt the trajectory toward end-stage kidney disease.

8. References

1. De Broe ME. (2016). Analgesic nephropathy: an underdiagnosed cause of chronic kidney disease. *Kidney Int.*;90(5):942-945.
2. Mihatsch MJ, Khanlari B, Brunner FP. (2017). Obituary to analgesic nephropathy: an autopsy-proven persistent clinical entity. *Nephrol Dial Transplant.*;32(7):1110-1115.
3. Lameire N, Van Biesen W, Vanholder R. (2018). Drug-induced acute kidney injury and chronic interstitial nephritis. *Lancet.*;392(10159):1720-1731.
4. Perazella MA. (2019). Drug-induced acute kidney injury: diverse mechanisms of tubular and tubulointerstitial injury. *Clin J Am Soc Nephrol.*;14(6):929-937.
5. Curhan GC, Knight BP, Rosner B, Hankinson SE, Stampfer MJ. (2017). Analgesic use and the risk of incidental hypertension and renal function decline. *N Engl J Med.*;376(14):1345-1353.

6. Ahsan MU, Ambreen U, Javed H, Noor N, Jan M, et al. (2025). NSAID-associated renal injury: mechanisms, risks, and safer strategies. *Arch Nephrol Ren Stud.*;5(1):1-5.
7. Markowitz GS, Perazella MA. (2020). Drug-induced tubulointerstitial nephritis: a modern clinical perspective. *Kidney Int Rep.*;5(8):1139-1149.
8. Moledina DG, Parikh CR. (2018). Phenotyping drug-induced acute kidney injury: focus on tubulointerstitial nephritis. *Clin J Am Soc Nephrol.*;13(7):1109-1117.
9. Naughton CA. (2019). Drug-induced nephrotoxicity: clinical patterns and prevention strategies. *Am Fam Physician.*;99(11):693-700.
10. Kaufman JP, Lasda E, Coleman CI. Over-the-counter analgesic consumption patterns and patient awareness of renal risks. *J Pharm Pract.* 2021;34(3):388-394.
11. Bennett WM. (2018). Chronic tubulointerstitial nephropathies: updating the analgesic paradigm. *Curr Opin Nephrol Hypertens.*;27(2):120-125.
12. Elseviers MM, De Broe ME. (2016). Analgesic nephropathy in the 21st century: changing patterns of combination abuse. *Nephron Clin Pract.*;133(4):c210-c218.
13. Chang SH, Mathew TH, McDonald SP. (2019). Analgesic nephropathy and end-stage renal disease: international trends and comorbidities. *Am J Kidney Dis.*;73(4):512-520.
14. Public Health England. (2022). Over-the-counter analgesic utilization and renal outcomes: a nationwide cohort study. *Br J Clin Pharmacol.*;88(9):4102-4112.
15. Varga Z, Sabzwari SR, Varghese V. (2017). Acute interstitial nephritis secondary to nonsteroidal anti-inflammatory drugs. *Am J Med Sci.*;354(5):519-526.
16. Radi ZA. (2019). Pathophysiology of drug-induced acute kidney injury and biomarkers. *Toxicol Pathol.*;47(8):922-931.
17. Forel CM, Eaves-Leanos A, Lindblad P. (2016). Combined analgesic use and risk of chronic renal failure. *J Am Soc Nephrol.*;27(8):2450-2458.
18. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. (2018). Long-term adverse renal and cardiovascular effects of paracetamol. *Br J Clin Pharmacol.*;84(10):2218-2230.
19. Koffman B, Bazzano LA. (2020). Multi-ingredient pain relievers and progressive renal insufficiency. *Pharmacotherapy.*;40(6):534-542.
20. Whelton A. (2019). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. *Am J Med.*;127(3S): S15-S22.
21. Baker M, Perazella MA. (2021). NSAIDs in chronic kidney disease: dangerous liaisons. *Semin Nephrol.*;41(1):42-53.
22. Sawawata T, Suzuki A, Mori M. (2020). Caffeine-containing combination analgesics and chronic kidney disease progression. *Clin Exp Nephrol.*;24(5):431-438.
23. Feenstra J, van der Laan JR, Grobbee DE. (2018). Cumulative dose relationships of nonsteroidal anti-inflammatory drugs and chronic renal impairment. *Pharmacoepidemiol Drug Saf.*;27(11):1240-1247.
24. Grantham JJ. (2017). Analgesic-induced renal papillary necrosis: cellular mechanisms and structural evolution. *Kidney Int.*;91(4):788-796.
25. Keen MU, Glasscock RJ. (2023). Analgesic nephropathy: clinical presentation and differential diagnosis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
26. Lucas G, Lebleu C. (2022). Drug-induced acute kidney injury in hospitalized internal medicine patients. *Eur J Intern Med.*;98:45-52.
27. Dhaun N, Bellamy CO, Casserly LF. (2019). Renal papillary necrosis: pathogenetic insights and diagnostic challenges. *Nephrol Dial Transplant.*;34(9):1441-1449.
28. Palmer BF, Clegg DJ. (2020). Renal hemodynamic effects of nonsteroidal anti-inflammatory drugs and COX-2 inhibitors. *Clin J Am Soc Nephrol.*;15(3):419-429.
29. Weir MR. (2018). Nonsteroidal anti-inflammatory drugs and the kidney: what the internist needs to know. *Physiol Rev.*;98(3):1421-1445.
30. Dreischulte T, Morales DR, Bell S, Guthrie B. (2017). Combining NSAIDs with RAAS inhibitors and diuretics: quantifiable risks of acute kidney injury. *BMJ.*;357: j2241.
31. Thomas MC. (2018). The triple whammy: ACE inhibitors, diuretics, and NSAIDs. *Med J Aust.*;209(10):432-436.
32. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. (2016). Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and nonsteroidal anti-inflammatory drugs and the risk of acute kidney injury. *BMJ.*;346: e8525.
33. Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A. (2018). NSAID use and risk of acute kidney injury in patients with hypertension. *Drug Saf.*;41(7):693-703.
34. Schnermann J. (2019). Autoregulation of renal blood flow and glomerular filtration rate: COX-2 and prostaglandin signaling. *Am J Physiol Renal Physiol.*;317(4):F871-F883.
35. Soni SS, Gowrishankar S, Besarab A. (2021). Chronic tubulointerstitial nephritis: dynamic interactions between tubular cells and interstitial myofibroblasts. *Am J Nephrol.*;252(6):441-453.
36. Breyer MD, Harris RC. (2018). Cyclooxygenase 2 and the kidney. *Curr Opin Nephrol Hypertens.*;27(5):367-375.
37. Hao CM, Breyer MD. (2017). Physiological and pathophysiological roles of lipid mediators in the kidney. *Kidney Int.*;92(5):1080-1091.
38. Imig JD. (2020). Eicosanoids and renal microvascular function in physiology and pathophysiology. *Physiol Rev.*;100(4):1585-1620.
39. Hansell P, Welch WJ, Blantz RC, Palm F. (2016). Determinants of kidney oxygenation and its role in acute and chronic kidney disease. *Acta Physiol (Oxf).*;216(1):33-48.
40. Evans RG, Ince C, Joles JA, Smith DW, May CN. (2020). Haemodynamic influences on kidney oxygenation: clinical implications for ischemic kidney injury. *Clin Exp Pharmacol Physiol.*;47(5):821-832.
41. O'Connor PM. (2017). Renal oxygenation and hypoxia in the pathogenesis of chronic kidney disease. *Curr Opin Nephrol Hypertens.*;26(4):287-292.
42. Bessems JG, Vermeulen NP. (2016). Paracetamol (acetaminophen)-induced toxicity: molecular mechanisms of reactive metabolite formation. *Crit Rev Toxicol.*;46(4):295-328.
43. Jaeschke H, Ramachandran A. (2018). Mechanisms of acetaminophen-induced cellular injury and necrosis. *Toxicol Sci.*;165(1):3-11.

44. Lorz C, Justo P, Sanz A, Subirá D, Egido J, Ortiz A. (2017). Paracetamol-induced renal tubular cell apoptosis: role of caspase activation and oxidative stress. *J Am Soc Nephrol.*;28(3):812-822.
45. McGill MR, Jaeschke H. (2019). Metabolism and disposition of acetaminophen: implications for nephrotoxicity. *Adv Pharmacol.*;85:115-140.
46. Mazer M, Perrone J. (2020). Acetaminophen-induced nephrotoxicity: pathomechanisms and clinical management. *J Med Toxicol.*;16(4):428-439.
47. Ghosh A, Sil PC. (2018). Anti-inflammatory and analgesic drug-induced hepatotoxicity and nephrotoxicity: cellular mechanisms. *Food Chem Toxicol.*;118:612-629.
48. Agarwal R. (2020). Nonsteroidal anti-inflammatory drugs, acetaminophen, and the kidney: a clinical update. *Adv Chronic Kidney Dis.*;27(1):38-46.
49. Remuzzi G, Ruggenti P. (2017). Prevention and treatment of chronic renal parenchymal disease. *N Engl J Med.*;377(8):751-762.
50. Zeier M, Ritz E. (2019). Analgesic nephropathy: an old problem in modern internal medicine. *Dtsch Arztebl Int.*;116(51-52):875-882.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI:10.31579/2690-4861/1162

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/international-journal-of-clinical-case-reports-and-reviews>